Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

Administration (FDA) of

a New Drug Application for ZEGERID (omeprazole/sodium bicarbonate) as a

branded over-the-counter product to treat frequent heartburn.

(Announced March 11)

-- The FDA's Advisory Committee on Anesthetics and Life Support

unanimously recommended approval of sugammadex, which if approved would

be the first and only selective relaxant binding agent for use with

surgical anesthesia. (Announced March 11)

-- Announced with Centocor, Inc. submission of a Marketing Authorization

Application to the European Medicines Agency requesting approval of

golimumab as a monthly subcutaneous treatment for adults with

rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

(Announced March 18)

-- Announced the launch of two new sunscreen products with an SPF of 70+,

the highest protection rating available to consumers in a continuous

spray. (Announced March 18)

-- Gained FDA approval of label revisions for PEGINTRON (peginterferon

alfa-2b) and REBETOL (ribavirin, USP) combination therapy for chronic

hepatitis C, recommending weight-based dosing of REBETOL based on

patient body weight. (Announced March 27)

-- The Merck/Schering-Plough joint venture announced results of the

ENHANCE ultrasound imaging trial. (Announced March 30)

-- Announced a major new Productivity Transformation Program (PTP) to

reduce and avoid costs and increase productivity to generate a total of

$1.5 billion in targeted annual savings and synergies. (Announced

April 2)

-- Announced adoption of a new governance requirement to strengthen the

alignment of executives with the interests of shareholders: a two-year

holding period for shares acquired by Executive Management Team members

upon the exercise of stock options. (Announced Apri
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and ... addition of Jain PharmaBiotech,s new report ... Companies" to their offering. ... report deals with therapeutic drug monitoring, a ... care by monitoring drug levels in the ...
(Date:5/28/2015)... May 27, 2015 Research and ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:5/28/2015)... , May 27, 2015 Research ... of Jain PharmaBiotech,s new report "Neuroprotection - ... This report describes the role of ... injuries of the nervous system as well as ... many of the underlying mechanisms of damage to ...
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3
... Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing ... Company will host a conference call and live audio ... 2009 to discuss its third quarter 2009 financial results ... call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The ...
... Oct. 30 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP Sunstone" ... , -- Oppenheimer 20th Annual Healthcare Conference, to be ... Waldorf=Astoria hotel in New York. Management is scheduled, ... and meet with, institutional investors throughout ...
... Sandia researchers have developed a process that can ... Researchers currently use all types of processes to ... small devices," says Sandia materials scientist Jim Martin "people ... to initiate mixing, but these approaches don,t work well." ...
Cached Biology Technology:BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009 2BMP Sunstone Announces November Investor Conference Participation 2Magnetic mixing creates quite a stir 2Magnetic mixing creates quite a stir 3
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... Scientists have found the "Rosetta Stone" of supervolcanoes, those ... and massive explosive eruptions that rank among nature,s most ... scale and possibly trigger climatic and environmental effects ... been discovered in the Italian Alps, Sesia Valley by ...
... BEER-SHEVA, September, 21 2009 A researcher who ... has demonstrated that it is possible to test and ... and to anticipate the immune response in Alzheimer,s patients. ... Negev could one day lead to specific Alzheimer,s vaccines ...
... Before it was learned that matter burns by taking ... the release of a mysterious substance, which they named ... chemists conduct experiments and share ideas. Only when it ... phlogiston did it become clear that no such thing ...
Cached Biology News:'Rosetta Stone' of supervolcanoes discovered in Italian Alps 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 3Ben-Gurion University Alzheimer's researcher demonstrates specific immune response to vaccine 2Echoes of phlogiston in stem cell biology 2